Fig. 3: Combining DNA repair modulation and cell-cycle synchronization synergistically enhances HDR in iPS cells.

a List of compounds tested with their function on molecular targets (top), and experimental timeline of compound pre- (4 h) and post-EP (48 h) treatment (bottom). b Screening of compounds under cold shock condition [C], including untreated (−) and DMSO treated (DMSO) controls, showing the effect on DNA repair outcome frequency. Data are presented as the mean ± S.D. of three biological replicates. c Ratio of HDR/MutEJ repair outcomes measured in b. d Combination treatment of NU7441 and SCR7 under cold shock condition [C], and the effect on repair outcome frequency. Data are presented as the mean of two biological replicates, except N + S is presented as the mean ± S.D. of four biological replicates. e Ratio of HDR/MutEJ repair outcomes measured in d. f Combination treatment of cell-cycle inhibitor XL413 (XL) post-EP (24 h) and N + S pre- (4 h) and post-EP (48 h) under normal culture conditions [A] or cold shock [C]. Data are presented as the mean ± S.D. of three technical replicates for each respective treatment. g Ratio of HDR/MutEJ repair outcomes measured in f. h Representative FACS plots of cells treated with XL413 (XL) and N + S under normal [A] (left) and cold shock [C] (right) conditions, as tested in f. Source data are provided as a Source Data file.